1. Proton pump inhibitors display anti‐tumour potential in glioma
   Bihan Li et al, 2023, Cell Proliferation CrossRef
2. Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
   Kim A. Papp et al, 2023, Dermatology and Therapy CrossRef
3. How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review
   Marco Carlo Merlano et al, 2022, Biomedicines CrossRef
4. State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan
   Yung-Hung Luo et al, 2022, International Journal of Molecular Sciences CrossRef
5. Head and neck squamous cell carcinoma: Exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy
   João Figueira Scarini et al, 2022, Critical Reviews in Oncology/Hematology CrossRef
6. Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
   Benjamin J. Solomon et al, 2024, JTO Clinical and Research Reports CrossRef
7. CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
   Alexandria TM Lee et al, 2023, Lung Cancer: Targets and Therapy CrossRef
8. Engineering Biomaterials to Model Immune‐Tumor Interactions In Vitro
   Arianna Skirzynska et al, 2024, Advanced Materials CrossRef
9. EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer
   Sook-hee Hong et al, 2022, Cancers CrossRef